All studies
Ongoing, recruitingTherapeutic use (Phase IV)Interventional
Treatment of non-type 2 CRSwNP with anti-IL-17 antibody (secukinumab)
At a glance
Status
Ongoing, recruiting
Phase
Therapeutic use (Phase IV)
Sponsor
Tartu University Hospital
Enrolment target
4
Start
11 Aug 2023
What is this study about?
mean change of NPS and SNOT-22 scores from baseline to week 16
Who may be eligible?
Age 18 Years to any · Sex: All
Locations (1)
- —Estonia
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.